One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis

Toru Inoue, Kazuyuki Numakura, Takahiro Osawa, Sei Naito, Takuma Ishihara, Kojiro Ohba, Kosuke Ueda, Yuya Sekine, Masaharu Oki, Hirohito Naito, Haruka Miyata, Hiroshi Kikuchi, Shin Kobayashi, Shintaro Narita, Norihiko Tsuchiya, Mikio Sugimoto, Tsukasa Igawa, Toshitaka Shin · 2026

Read One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis by Toru Inoue, Kazuyuki Numakura, Takahiro Osawa, Sei Naito, Takuma Ishihara, Kojiro Ohba, Kosuke Ueda, Yuya Sekine, Masaharu Oki, Hirohito Naito, Haruka Miyata, Hiroshi Kikuchi, Shin Kobayashi, Shintaro Narita, Norihiko Tsuchiya, Mikio Sugimoto, Tsukasa Igawa, Toshitaka Shin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13631030.txt.

Description

Toru Inoue and co-authors present a 2026 study hunting for an early warning sign in kidney cancer immunotherapy. The drug pair nivolumab plus ipilimumab can control metastatic kidney cancer for years, but some patients crash before the first scan at twelve weeks. The team tracked six blood inflammation markers in two hundred nineteen patients across eight Japanese hospitals, checking which early change predicted survival.

The one-week mark spoke loudest. A composite marker called the pan-immune-inflammation value rose in sixty percent of patients with paired samples, and that rise, counterintuitively, predicted better survival even after adjustment. The authors suggest a simple blood test one week into treatment could flag who is on a good path long before imaging can.

Catalog record

CREATORToru Inoue, Kazuyuki Numakura, Takahiro Osawa, Sei Naito, Takuma Ishihara, Kojiro Ohba, Kosuke Ueda, Yuya Sekine, Masaharu Oki, Hirohito Naito, Haruka Miyata, Hiroshi Kikuchi, Shin Kobayashi, Shintaro Narita, Norihiko Tsuchiya, Mikio Sugimoto, Tsukasa Igawa, Toshitaka Shin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13631030

Browse the full library · About the Tower of Babel